Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors.
Sho Tazuma, Takeshi Sudo, Kenta Baba et al.
✦ AI-curated · Sources linked
Case in brief
A 78-year-old woman was diagnosed with metastatic pancreatic ductal adenocarcinoma involving the liver. Tumour testing identified a GP2-NTRK1 fusion. She received gemcitabine plus nab-paclitaxel, followed by the TRK inhibitors entrectinib and larotrectinib. The reported outcome was survival exceeding 54 months from diagnosis and 34 months from starting TRK inhibitor therapy.
What made this case unusual
The tumour harboured a GP2-NTRK1 fusion, and the report describes prolonged survival after sequential chemotherapy and two TRK inhibitors in metastatic pancreatic ductal adenocarcinoma.
Diagnostic / clinical pearl
Molecular testing can identify an NTRK fusion in pancreatic ductal adenocarcinoma, as illustrated by this GP2-NTRK1-positive case.